Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 22, 2022

Tumor Immune Contexture Is a Determinant of Anti-CD19 CAR T-Cell Therapy Efficacy in LBCL

Nature Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

Nature Medicine
Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
Nat. Med. 2022 Aug 29;[EPub Ahead of Print], N Scholler, R Perbost, FL Locke, MD Jain, S Turcan, C Danan, EC Chang, SS Neelapu, DB Miklos, CA Jacobson, LJ Lekakis, Y Lin, A Ghobadi, JJ Kim, J Chou, V Plaks, Z Wang, A Xue, M Mattie, JM Rossi, A Bot, J Galon

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading